Sibelius: LactoMato is a clinically evidenced, enhanced bioavailability lycopene complex specifically developed to promote healthy sperm function and support prostate and cardiovascular health. Lycopene is considered one of the strongest antioxidants of bioactive carotenoids, but it is poorly absorbed by humans. Sibelius’ patented formulation of LactoLycopene improves solubility and bioavailability to provide a more efficacious ingredient, according to the company.
A recent 12-week, double-blind, placebo-controlled human clinical trial performed at the University of Sheffield, revealed that Sibelius: LactoMato displayed significant results on semen quality at a 14 mg dose, when compared to the placebo group. The study demonstrated that trial applicants who supplemented with Sibelius: LactoMato, increased the proportions of healthy sperm and boosted sperm speed by up to 40%.
“The improved bioavailability of LactoLycopene allows the body to get the most out of this potent antioxidant; potentially protecting semen from oxidative stress and promoting higher concentration and quality of produced sperm,” said Kieron Edwards, chief scientific officer at Sibelius Natural Products. “The results from the trial show that Sibelius: LactoMato has great potential to improve men’s health. We look forward to our continued research of this ingredients efficacy in further human clinical trials.”